Adaptive Biotechnologies (ADPT) Revenue (2018 - 2026)

Adaptive Biotechnologies has disclosed Revenue across 9 years of filings, most recently posting $71.6 million for Q2 2026.

• In Q2 2026, Revenue rose 21.53% year-over-year to $71.6 million; the TTM figure through Jun 2026 stood at $308.1 million (up 50.13% YoY), while the FY2025 annual figure was $277.0 million, up 54.77% from the prior year.
• Revenue came in at $71.6 million for Q2 2026 at Adaptive Biotechnologies, up from $70.9 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $94.0 million in Q3 2025 to a low of $37.6 million in Q1 2023.
• Average Revenue over 5 years is $53.0 million, with a median of $47.6 million recorded in 2022.
• Year-over-year, Revenue dropped 20.72% in 2023 and soared 102.38% in 2025.
• Over 5 years, Revenue stood at $55.2 million in 2022, then retreated by 17.05% to $45.8 million in 2023, then rose by 3.66% to $47.5 million in 2024, then surged by 51.04% to $71.7 million in 2025, then fell by 0.18% to $71.6 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $71.6 million in Q2 2026, $70.9 million in Q1 2026, and $71.7 million in Q4 2025.